GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Treace Medical Concepts Inc (NAS:TMCI) » Definitions » Peter Lynch Fair Value

Treace Medical Concepts (Treace Medical Concepts) Peter Lynch Fair Value : N/A (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Treace Medical Concepts Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Treace Medical Concepts's Peter Lynch Fair Value or its related term are showing as below:



TMCI's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.61
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Treace Medical Concepts Peter Lynch Fair Value Historical Data

The historical data trend for Treace Medical Concepts's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treace Medical Concepts Peter Lynch Fair Value Chart

Treace Medical Concepts Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
- - - - -

Treace Medical Concepts Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Treace Medical Concepts's Peter Lynch Fair Value

For the Medical Devices subindustry, Treace Medical Concepts's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Treace Medical Concepts's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Treace Medical Concepts's Price-to-Peter-Lynch-Fair-Value falls into.



Treace Medical Concepts Peter Lynch Fair Value Calculation

Treace Medical Concepts's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.81
=N/A

Treace Medical Concepts's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-0.81.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Treace Medical Concepts  (NAS:TMCI) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Treace Medical Concepts's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=5.91/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Treace Medical Concepts Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Treace Medical Concepts's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Treace Medical Concepts (Treace Medical Concepts) Business Description

Traded in Other Exchanges
N/A
Address
100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
Executives
F Barry Bays director
Betsy Hanna director C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sean F. Scanlan officer: See Remarks C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
James T Treace director 117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Thomas E Timbie director
Daniel E. Owens officer: Chief HR Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Scot Michael Elder officer: *See "Remarks" C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Mark Hair officer: Chief Financial Officer C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Aaron Berutti officer: Sr. VP, Sales C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
John T. Treace director, 10 percent owner, officer: Chief Executive Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Lance A Berry director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John R Treace director 5677 AIRLINE RD, ARLINGTON VA 38002

Treace Medical Concepts (Treace Medical Concepts) Headlines

From GuruFocus

Treace to Report First Quarter 2023 Financial Results on May 8, 2023

By sperokesalga sperokesalga 04-20-2023

Treace Medical Concepts, Inc. Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 02-07-2023